CN1250220C - 类大麻碱中心受体拮抗剂在制造用于使停止烟草消费容易化的药物中的应用 - Google Patents

类大麻碱中心受体拮抗剂在制造用于使停止烟草消费容易化的药物中的应用 Download PDF

Info

Publication number
CN1250220C
CN1250220C CNB018047130A CN01804713A CN1250220C CN 1250220 C CN1250220 C CN 1250220C CN B018047130 A CNB018047130 A CN B018047130A CN 01804713 A CN01804713 A CN 01804713A CN 1250220 C CN1250220 C CN 1250220C
Authority
CN
China
Prior art keywords
nicotine
administration
tobacco consumption
active component
compd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018047130A
Other languages
English (en)
Chinese (zh)
Other versions
CN1406128A (zh
Inventor
J·C·布兰查尔德
F·梅纳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA, Sanofi Aventis France filed Critical Sanofi Synthelabo SA
Publication of CN1406128A publication Critical patent/CN1406128A/zh
Application granted granted Critical
Publication of CN1250220C publication Critical patent/CN1250220C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB018047130A 2000-02-09 2001-02-07 类大麻碱中心受体拮抗剂在制造用于使停止烟草消费容易化的药物中的应用 Expired - Fee Related CN1250220C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR00/01682 2000-02-09
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Publications (2)

Publication Number Publication Date
CN1406128A CN1406128A (zh) 2003-03-26
CN1250220C true CN1250220C (zh) 2006-04-12

Family

ID=8846875

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018047130A Expired - Fee Related CN1250220C (zh) 2000-02-09 2001-02-07 类大麻碱中心受体拮抗剂在制造用于使停止烟草消费容易化的药物中的应用

Country Status (32)

Country Link
US (2) US6930122B2 (cg-RX-API-DMAC7.html)
EP (1) EP1257275B1 (cg-RX-API-DMAC7.html)
JP (2) JP2003522145A (cg-RX-API-DMAC7.html)
CN (1) CN1250220C (cg-RX-API-DMAC7.html)
AR (1) AR028505A1 (cg-RX-API-DMAC7.html)
AT (1) ATE292467T1 (cg-RX-API-DMAC7.html)
AU (1) AU781827B2 (cg-RX-API-DMAC7.html)
BG (2) BG110386A (cg-RX-API-DMAC7.html)
BR (1) BR0108126A (cg-RX-API-DMAC7.html)
CA (1) CA2397262C (cg-RX-API-DMAC7.html)
CZ (1) CZ296685B6 (cg-RX-API-DMAC7.html)
DE (1) DE60109903T2 (cg-RX-API-DMAC7.html)
DK (1) DK1257275T3 (cg-RX-API-DMAC7.html)
EE (1) EE04836B1 (cg-RX-API-DMAC7.html)
ES (1) ES2240416T3 (cg-RX-API-DMAC7.html)
FR (1) FR2804604B1 (cg-RX-API-DMAC7.html)
HU (1) HU225328B1 (cg-RX-API-DMAC7.html)
IL (1) IL150710A0 (cg-RX-API-DMAC7.html)
IS (1) IS6450A (cg-RX-API-DMAC7.html)
MX (1) MXPA02007766A (cg-RX-API-DMAC7.html)
NO (1) NO324521B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ519924A (cg-RX-API-DMAC7.html)
PL (1) PL201685B1 (cg-RX-API-DMAC7.html)
PT (1) PT1257275E (cg-RX-API-DMAC7.html)
RS (1) RS50404B (cg-RX-API-DMAC7.html)
RU (1) RU2257207C2 (cg-RX-API-DMAC7.html)
SI (1) SI1257275T1 (cg-RX-API-DMAC7.html)
SK (1) SK284952B6 (cg-RX-API-DMAC7.html)
TW (1) TWI243677B (cg-RX-API-DMAC7.html)
UA (1) UA72783C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001058450A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200205317B (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
AU2002356039A1 (en) 2001-08-13 2003-03-03 Honeywell International Inc. Methods of conducting wafer level burn-in of electronic devices
JP2005533748A (ja) 2002-03-08 2005-11-10 シグナル ファーマシューティカルズ，インコーポレイテッド 増殖性障害および癌を治療、予防、または管理するための併用療法
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
JP2005528366A (ja) 2002-03-26 2005-09-22 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体モジュレータとしてのスピロ環式アミド
JP2005531520A (ja) 2002-03-28 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド 置換２，３−ジフェニルピリジン類
WO2003086288A2 (en) 2002-04-12 2003-10-23 Merck & Co., Inc. Bicyclic amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
CA2499497A1 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2004058145A2 (en) 2002-12-19 2004-07-15 Merck & Co., Inc. Substituted amides
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
CA2526103A1 (en) * 2003-05-20 2004-12-29 Bob M. Ii Moore Cannabinoid derivatives, methods of making, and use thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
CA2543882A1 (en) * 2003-10-30 2005-05-19 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
MX2007000491A (es) 2004-07-12 2007-03-28 Cadila Healthcare Ltd Nuevos compuestos heterociclicos.
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
ES2435790T3 (es) 2004-12-03 2013-12-23 Intervet International B.V. Piperazinas sustituidas como antagonistas de CB1
NZ569814A (en) * 2006-01-18 2011-10-28 Schering Corp Cannibinoid receptor modulators
WO2007121687A1 (en) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2477634C2 (ru) * 2006-06-16 2013-03-20 Теракос, Инк. Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
WO2008046905A1 (en) * 2006-10-20 2008-04-24 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
WO2009005671A2 (en) * 2007-06-28 2009-01-08 Schering Corporation Substituted piperazines as cb1 antagonists
EP2170846A2 (en) * 2007-06-28 2010-04-07 Intervet International BV Substituted piperazines as cb1 antagonists
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Also Published As

Publication number Publication date
CA2397262A1 (en) 2001-08-16
CA2397262C (en) 2007-09-11
US20030087933A1 (en) 2003-05-08
YU59002A (sh) 2005-07-19
US20050187253A1 (en) 2005-08-25
PL358221A1 (en) 2004-08-09
IS6450A (is) 2002-06-28
BG106946A (bg) 2003-05-30
PT1257275E (pt) 2005-07-29
EP1257275B1 (fr) 2005-04-06
HUP0300237A2 (hu) 2003-07-28
NZ519924A (en) 2005-01-28
HK1051140A1 (en) 2003-07-25
AU3562001A (en) 2001-08-20
RU2002118309A (ru) 2004-02-20
AU781827B2 (en) 2005-06-16
NO20023765D0 (no) 2002-08-08
MXPA02007766A (es) 2002-10-11
EE04836B1 (et) 2007-06-15
BR0108126A (pt) 2003-01-28
ATE292467T1 (de) 2005-04-15
DE60109903D1 (de) 2005-05-12
JP2010018622A (ja) 2010-01-28
FR2804604B1 (fr) 2005-05-27
IL150710A0 (en) 2003-02-12
WO2001058450A3 (fr) 2002-04-25
SK284952B6 (sk) 2006-03-02
US6930122B2 (en) 2005-08-16
CZ296685B6 (cs) 2006-05-17
NO20023765L (no) 2002-10-09
DE60109903T2 (de) 2006-02-09
TWI243677B (en) 2005-11-21
JP2003522145A (ja) 2003-07-22
BG110386A (en) 2009-09-30
SI1257275T1 (en) 2005-10-31
NO324521B1 (no) 2007-11-12
ZA200205317B (en) 2003-09-04
EE200200439A (et) 2003-12-15
RS50404B (sr) 2009-12-31
DK1257275T3 (da) 2005-08-08
HUP0300237A3 (en) 2003-09-29
AR028505A1 (es) 2003-05-14
FR2804604A1 (fr) 2001-08-10
PL201685B1 (pl) 2009-04-30
HU225328B1 (en) 2006-09-28
SK11292002A3 (sk) 2003-02-04
WO2001058450A2 (fr) 2001-08-16
RU2257207C2 (ru) 2005-07-27
BG65856B1 (bg) 2010-03-31
UA72783C2 (en) 2005-04-15
CN1406128A (zh) 2003-03-26
EP1257275A2 (fr) 2002-11-20
ES2240416T3 (es) 2005-10-16
CZ20022698A3 (cs) 2002-11-13

Similar Documents

Publication Publication Date Title
CN1250220C (zh) 类大麻碱中心受体拮抗剂在制造用于使停止烟草消费容易化的药物中的应用
CN1227002C (zh) 包含聚醋酸乙烯酯和聚乙烯基吡咯烷酮的含活性成分漂浮形式及其用途与制备
US8486450B2 (en) Method of producing solid preparation disintegrating in the oral cavity
JP2021006534A (ja) 新規製剤
US8513439B2 (en) Antidepressant oral pharmaceutical compositions
JPH10510559A (ja) シサプリドの即時放出性ｐＨ非依存性固形製剤
HUE035542T2 (hu) Brexpiprazolt vagy annak sóját és egy második hatóanyagot tartalmazó kombinációk központi idegrendszeri rendellenességek kezelésében történõ alkalmazásra
CN1257422A (zh) 固体药物制剂
JPH08208471A (ja) 薬物反応の増強作用
US20210047268A1 (en) Methods for inhibiting native and promiscuous uptake of monoamine neurotransmistters
TW200914066A (en) Solid preparation
EP2124901A1 (en) Tablet preparation without causing a tableting trouble
RS59002B1 (sr) Pirimido[4,5-b]indol derivati i njihova primena u ekspanziji hematopoetskih matičnih ćelija
CN1271276A (zh) 经舌下或含服给药的控释药物
JP2007518755A (ja) モノアミン神経伝達物質再取り込み阻害剤及びｎ−メチル−ｄ−アスパラギン酸（ｎｍｄａ）受容体アンタゴニストを含む医薬組成物
JP2002541098A (ja) ジプラシドン代謝産物を用いる神経弛緩薬性障害および関連障害を治療するための方法および組成物
CN101500567B (zh) P38激酶抑制剂治疗精神障碍的用途
JP2002538102A (ja) 光学的に純粋なｒ（＋）オンダンセトロンを使用する無呼吸および無呼吸障害の治療方法
FR2900823A1 (fr) Nouvelle forme d'administration du racecadotril.
US20060079569A1 (en) Antidepressant oral liquid compositions
CN1642532A (zh) 曲马多缓释制剂
CN104519874B (zh) 固体制剂
CN1250208C (zh) 氟西汀肠溶片
WO2001093844A2 (en) Compositions comprising a serotonin transporter inhibitor and a 5-ht1d antagonist
JP7751354B1 (ja) 結晶の製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060412

Termination date: 20100207